HC Wainwright Reiterates Buy Rating for Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science (NASDAQ:FCSC)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Friday, TipRanks reports. They currently have a $20.00 target price on the stock.

Several other brokerages have also recently commented on FCSC. Zacks Investment Research upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. ValuEngine upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

FCSC traded down $0.02 during midday trading on Friday, hitting $1.88. The company had a trading volume of 54,035 shares, compared to its average volume of 450,241. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.50 and a current ratio of 3.50. The company has a market capitalization of $18.64 million, a PE ratio of -1.30 and a beta of 1.60. Fibrocell Science has a twelve month low of $1.45 and a twelve month high of $3.28. The firm’s 50-day simple moving average is $1.83 and its 200-day simple moving average is $1.98.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $1.30. The company had revenue of $21.79 million during the quarter. As a group, sell-side analysts anticipate that Fibrocell Science will post 0.1 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Morgan Stanley grew its position in shares of Fibrocell Science by 13.2% during the 2nd quarter. Morgan Stanley now owns 59,900 shares of the company’s stock worth $114,000 after buying an additional 7,000 shares during the period. Virtu Financial LLC grew its position in shares of Fibrocell Science by 90.7% during the 1st quarter. Virtu Financial LLC now owns 39,864 shares of the company’s stock worth $77,000 after buying an additional 18,958 shares during the period. Apis Capital Advisors LLC acquired a new position in Fibrocell Science during the first quarter valued at approximately $48,000. Bank of Montreal Can acquired a new position in Fibrocell Science during the second quarter valued at approximately $71,000. Finally, Renaissance Technologies LLC grew its holdings in Fibrocell Science by 38.0% during the second quarter. Renaissance Technologies LLC now owns 740,454 shares of the company’s stock valued at $1,407,000 after purchasing an additional 204,015 shares during the period. Institutional investors own 29.55% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Read More: What is the operating income formula?

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.